Previous 10 | Next 10 |
Achaogen (NASDAQ: AKAO ) -37% on pricing stock and warrant offering. More news on: Achaogen, Marin Software, TrueCar, Inc, Stocks on the move, Read more ...
Achaogen (NASDAQ: AKAO ) prices its public offering of 15M shares of common stock and short-term warrants to purchase up to 15M common shares and long-term warrants at a price $1.00 per share/warrant, for gross proceeds of $15M. More news on: Achaogen, Healthcare stocks news, Stocks on t...
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of...
Achaogen (NASDAQ: AKAO ) has slid 23.9% on heavy after-hours volume after proposing a public offering of its common stock. More news on: Achaogen, Healthcare stocks news, Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has c...
On June 26, 2019, Achaogen (AKAO) announced mixed news to its anxious investors - the company's lead drug candidate, the antibiotic Zemdri (plazomicin), had been approved for the treatment of complicated urinary tract infections (cUTI), but had received a CRL for its potential indication for...
-- Company provides update on ZEMDRI ® commercialization and launch -- -- Data from both the EPIC and CARE Phase 3 clinical studies of plazomicin are expected in peer-reviewed publication -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaog...
-- Plazomicin may be well-suited to play a critical role in biodefense preparedness -- SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial age...
Gainers: Fortress Biotech (NASDAQ: FBIO ) +41% . MeiraGTx Holdings (NASDAQ: MGTX ) +29% . Eldorado Gold (NYSE: EGO ) +23% . Avon Products (NYSE: AVP ) +22% . Silicom (NASDAQ: SILC ) +20% . Onconova Therapeutics (NASDAQ: ONTX ) +20% . 1-800-FLOWERS.COM (NASDAQ: FLWS ) +19% . Tu...
Gainers: Organogenesis Holdings ( ORGO ) +57% . Rand Capital (NASDAQ: RAND ) +32% . PHI (NASDAQ: PHII ) +26% . ClearOne (NASDAQ: CLRO ) +23% . Bristow Group (NYSE: BRS ) +20% . Digital Ally (NASDAQ: DGLY ) +17% . SITO Mobile (NASDAQ: SITO ) +16% . Achaogen (NASDAQ: AKAO ) +16% . C...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today it has reached agreements to sell substan...
SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today that it has filed a volun...
-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives -- -- Conference call today at 4:30 p.m. Eastern Time -- SOUTH S...